Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Personalized risk-profiling for acute leukemia patients undergoing haploidentical allo-HCT

Arnon Nagler • 10 Dec 2020
ASH 2020
Leukemia

Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, outlines a study investigating a novel approach to personalized risk-profiling for acute leukemia patients undergoing haploidentical allogeneic hematopoietic stem cell transplantation (allo-HCT). The study analyzed data from 2001 patients in the European Society for Blood and Marrow Transplantation registry who underwent haploidentical allo-HCT for acute leukemia, and models were developed to explore leukemia-free survival outcomes in these patients. The approach will allow the use of risk-guided interventions in patients with leukemia. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from Arnon Nagler

2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:21
Trends in alloSCT for good-risk AML: a longitudinal study
Arnon Nagler • 9 Dec 2023
2:15
GvHD prophylaxis post-alloSCT: PTCy versus ATG
Arnon Nagler • 9 Dec 2023
2:13
Haploidentical SCT for the treatment of secondary AML
Arnon Nagler • 9 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals